Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 20, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	12,300	13,160	1,829	897	263	387
Market Cap Growth	-19.11%	619.43%	103.94%	241.23%	-32.01%	-28.06%
Enterprise Value	12,040	12,705	1,737	779	184	366
Last Close Price	15.87	17.84	2.61	4.25	2.69	4.70
PS Ratio	-	-	-	1272.24	145.30	449.56
PB Ratio	61.45	33.85	23.54	7.08	3.16	4.87
P/TBV Ratio	64.50	34.02	24.13	7.18	3.71	5.87
EV/Sales Ratio	-	-	-	1105.42	101.96	425.47
Debt / Equity Ratio	0.03	0.02	1.37	4.10	0.03	0.01
Net Debt / Equity Ratio	-1.21	-1.04	-1.03	1.34	-0.83	-0.83
Net Debt / EBITDA Ratio	0.25	1.92	0.91	-2.73	0.81	1.30
Net Debt / FCF Ratio	0.86	2.85	1.04	-4.03	0.95	1.36
Asset Turnover	-	-	-	0.00	0.02	0.01
Quick Ratio	3.67	9.90	9.17	9.15	3.47	3.85
Current Ratio	3.80	10.15	9.30	16.93	3.80	4.41
Return on Equity (ROE)	-292.49%	-94.89%	-601.85%	-75.05%	-108.89%	-66.57%
Return on Assets (ROA)	-152.88%	-41.30%	-12.79%	-10.23%	-49.91%	-32.91%
Return on Capital Employed (ROCE)	-475.20%	-53.60%	-48.60%	-10.20%	-98.20%	-63.40%
Earnings Yield	-7.51%	-1.68%	-33.62%	-8.78%	-33.71%	-13.63%
FCF Yield	-2.20%	-1.08%	-4.20%	-4.71%	-27.73%	-12.55%
Buyback Yield / Dilution	-4.36%	-15.96%	-220.50%	-109.60%	-32.67%	-111.78%

Updated Oct 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q